DOCSLIB.ORG

Ergot Alkaloid Biosynthesis in Aspergillus Fumigatus : Association with Sporulation and Clustered Genes Common Among Ergot Fungi

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Graduate Theses, Dissertations, and Problem Reports 2009 Ergot alkaloid biosynthesis in Aspergillus fumigatus : Association with sporulation and clustered genes common among ergot fungi Christine M. Coyle West Virginia University Follow this and additional works at: https://researchrepository.wvu.edu/etd Recommended Citation Coyle, Christine M., "Ergot alkaloid biosynthesis in Aspergillus fumigatus : Association with sporulation and clustered genes common among ergot fungi" (2009). Graduate Theses, Dissertations, and Problem Reports. 4453. https://researchrepository.wvu.edu/etd/4453 This Dissertation is protected by copyright and/or related rights. It has been brought to you by the The Research Repository @ WVU with permission from the rights-holder(s). You are free to use this Dissertation in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in WVU Graduate Theses, Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU. For more information, please contact [email protected]. Ergot alkaloid biosynthesis in Aspergillus fumigatus: Association with sporulation and clustered genes common among ergot fungi Christine M. Coyle Dissertation submitted to the Davis College of Agriculture, Forestry, and Consumer Sciences at West Virginia University in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Genetics and Developmental Biology Daniel G. Panaccione, Ph.D., Chair Kenneth P. Blemings, Ph.D. Joseph B. Morton, Ph.D. Alan J. Sexstone, Ph.D. Sharon L. Wenger, Ph.D. Division of Plant and Soil Sciences Morgantown, West Virginia 2009 Keywords: Aspergillus fumigatus, ergot alkaloid biosynthesis, sporulation Copyright 2009 Christine M. Coyle ABSTRACT Ergot alkaloid biosynthesis in Aspergillus fumigatus: Association with sporulation and clustered genes common among ergot fungi Christine M. Coyle Ergot alkaloids, indole-derived mycotoxins, interact with multiple monoamine neurotransmitter receptors and cause disease in exposed individuals. They have been well studied in the ergot fungus, Claviceps purpurea, and have been reported in some closely related grass endophytes, as well as the distantly related opportunistic human pathogen Aspergillus fumigatus. A. fumigatus, which sporulates prolifically, produces clavines, specifically festuclavine and fumigaclavines A, B, and C in association with asexual spores and the total mass of alkaloids constitutes over 1% of the spore mass. These alkaloids differ from those of most clavicipitaceous fungi, which consist of different clavines and often more complex lysergic acid derivatives. However, the ergot alkaloid pathways of A. fumigatus and ergot fungi are hypothesized to share early biosynthetic steps, diverging at some point after the formation of the intermediate chanoclavine. A homologue of dmaW, a gene encoding dimethylallyltryptophan synthase in Neotyphodium endophytes, was found in the A. fumigatus genome. By gene knockout analysis, dmaW was shown to be required for ergot alkaloid production in A. fumigatus. Comparison of genes clustered around A. fumigatus dmaW to those clustered with dmaW in the ergot fungi revealed potential homologues that could encode proteins controlling early, shared steps in the pathway. Functional analysis via gene knockout of three additional A. fumigatus genes (easA, easE, and easF) rendered mutants with altered alkaloid profiles, demonstrating their involvement in ergot alkaloid biosynthesis. All mutants lacked normal ergot alkaloid production from the latter part of the pathway; complementation with a functional copy of the respective gene, restored normal ergot alkaloid production in each mutant. Analyses of intermediates positioned the products of easF and easE as the second and third enzymatic steps of the pathway. Knockout of easA caused accumulation of multiple intermediates, including chanoclavine; complementation with the C. purpurea easA gene resulted in accumulation of agroclavine, setoclavine, and its isomer isosetoclavine. These data confirm easA involvement post chanoclavine synthesis and more specifically assign its role to reduction of chanoclavine aldehyde, the branch point of the two lineage-specific pathways. These mutants, due to their differing ergot alkaloid profiles, are valuable for testing the role of specific ergot alkaloids in animal pathogenesis and toxicoses. Elucidation of ergot alkaloid biosynthesis, along with the capacity to control the spectrum of alkaloids produced, may be beneficial to agriculture and medicine. Additional studies demonstrated that production of ergot alkaloids was restricted to conidiating cultures. Disruption of brlA, a regulatory gene involved in conidiation, interfered with conidiophore development, as well as ergot alkaloid production. The association of these toxins with sporulation may offer insight into their ecological significance and utility to the fungus. DEDICATION I would like to dedicate this research to my advisor, Dr. Dan Panaccione. His vision and guidance has made this research possible. He has approached the project with overwhelming insight and enthusiasm, providing encouragement and enlightenment along the way. I appreciate the time and energy he has devoted to teaching and mentoring me as a graduate student. I am extremely grateful for his support, patience, and understanding during my years here at WVU, which made it possible to pursue this degree while balancing life as a mother and wife. It truly has been a privilege to work with Dan. He has helped lay my foundation for success and for this I will be forever thankful. iii ACKNOWLEDGEMENTS It is through the support of others that we can accomplish great things. First, I would like to thank my advisor, Dr. Dan Panaccione, and my committee members, Dr. Sharon Wenger, Dr. Ken Blemings, Dr. Joe Morton, and Dr. Alan Sexstone for their assistance and guidance throughout my Ph.D. pursuit. Dr. Dale Karlson, Dr. Jed Doelling, Dr. Joginder Nath, and Dr. Barton Baker have also provided assistance during my time at WVU, along with the Plant and Soil Science administrative assistants. Many thanks to Sherie Edenborn, Kerry Goetz, Shanthi Mulinti, Dawn Chamberlain, Mike Hamstead, and Brian Lewis for their laboratory assistance. I truly cherish the moments I have spent with my dear colleagues and friends within Environmental Microbiology and Plant Pathology. I am grateful for their support, advice, and camaraderie. I would especially like to recognize Bill Wheeler, Mark Double, Dr. Gary Bissonnette, Sherie Edenborn, Kerry Goetz, Shanthi Mulinti, Dawn Chamberlain, Tiara King, Emily Markle, Zola Msiska, Kelly Mayhew, Brian Lewis, Shawn Kenaley, and Bill Rittenour. In addition, I will never forget the lunch bunch, (This includes you, Dr. Gallegly) for the exhilarating and often enlightening conversations. I have been blessed with the constant love and support of my family and friends. My parents have provided me with endless guidance and encouragement. My siblings have enriched my life through their friendship. I feel fortunate for the encouragement and support of my in-laws over the last several years. Their willingness to care for my daughter, Grace, has made this experience easier. Grace has been a blessing throughout this endeavor. Her sweet and loving nature is a wonderful welcome, especially after a long day. And last, but definitely not least, my husband Andrew. I am so grateful for his support, love, and encouragement, especially this last year. Keeping life together, especially in the last few months, has been a challenge and his support has made it possible. I have had a wonderful experience at WVU and will cherish these memories always! iv Table of Contents ABSTRACT ............................................................................................................................................. ii DEDICATION ......................................................................................................................................... iii ACKNOWLEDGEMENTS ......................................................................................................................... iv LIST OF TABLES ................................................................................................................................... viii LIST OF FIGURES ................................................................................................................................. viii REVIEW OF LITERATURE ........................................................................................................................ 1 OVERVIEW ................................................................................................................................................. 1 ERGOT ALKALOIDS AND THEIR HISTORICAL SIGNIFICANCE ....................................................................... 1 CLASSES OF ERGOT ALKALOIDS .................................................................................................................. 4 ERGOT ALKALOID PRODUCING FUNGI ....................................................................................................... 6 ERGOT ALKALOID SYNTHESIS GENE CLUSTERS .........................................................................................
Recommended publications
  • Allergic Bronchopulmonary Aspergillosis Revealing Asthma

    Allergic Bronchopulmonary Aspergillosis Revealing Asthma

    CASE REPORT published: 22 June 2021 doi: 10.3389/fimmu.2021.695954 Case Report: Allergic Bronchopulmonary Aspergillosis Revealing Asthma Houda Snen 1,2*, Aicha Kallel 2,3*, Hana Blibech 1,2, Sana Jemel 2,3, Nozha Ben Salah 1,2, Sonia Marouen 3, Nadia Mehiri 1,2, Slah Belhaj 3, Bechir Louzir 1,2 and Kalthoum Kallel 2,3 1 Pulmonary Department, Hospital Mongi Slim, La Marsa, Tunisia, 2 Faculty of Medicine, Tunis El Manar University, Tunis, Tunisia, 3 Parasitology and Mycology Department, La Rabta Hospital, Tunis, Tunisia Allergic bronchopulmonary aspergillosis (ABPA) is an immunological pulmonary disorder caused by hypersensitivity to Aspergillus which colonizes the airways of patients with asthma and cystic fibrosis. Its diagnosis could be difficult in some cases due to atypical Edited by: presentations especially when there is no medical history of asthma. Treatment of ABPA is Brian Stephen Eley, frequently associated to side effects but cumulated drug toxicity due to different molecules University of Cape Town, South Africa is rarely reported. An accurate choice among the different available molecules and Reviewed by: effective on ABPA is crucial. We report a case of ABPA in a woman without a known Shivank Singh, Southern Medical University, China history of asthma. She presented an acute bronchitis with wheezing dyspnea leading to an Richard B. Moss, acute respiratory failure. She was hospitalized in the intensive care unit. The Stanford University, United States bronchoscopy revealed a complete obstruction of the left primary bronchus by a sticky *Correspondence: Houda Snen greenish material. The culture of this material isolated Aspergillus fumigatus and that of [email protected] bronchial aspiration fluid isolated Pseudomonas aeruginosa.
  • Ergot Alkaloids Mycotoxins in Cereals and Cereal-Derived Food Products: Characteristics, Toxicity, Prevalence, and Control Strategies

    Ergot Alkaloids Mycotoxins in Cereals and Cereal-Derived Food Products: Characteristics, Toxicity, Prevalence, and Control Strategies

    agronomy Review Ergot Alkaloids Mycotoxins in Cereals and Cereal-Derived Food Products: Characteristics, Toxicity, Prevalence, and Control Strategies Sofia Agriopoulou Department of Food Science and Technology, University of the Peloponnese, Antikalamos, 24100 Kalamata, Greece; [email protected]; Tel.: +30-27210-45271 Abstract: Ergot alkaloids (EAs) are a group of mycotoxins that are mainly produced from the plant pathogen Claviceps. Claviceps purpurea is one of the most important species, being a major producer of EAs that infect more than 400 species of monocotyledonous plants. Rye, barley, wheat, millet, oats, and triticale are the main crops affected by EAs, with rye having the highest rates of fungal infection. The 12 major EAs are ergometrine (Em), ergotamine (Et), ergocristine (Ecr), ergokryptine (Ekr), ergosine (Es), and ergocornine (Eco) and their epimers ergotaminine (Etn), egometrinine (Emn), egocristinine (Ecrn), ergokryptinine (Ekrn), ergocroninine (Econ), and ergosinine (Esn). Given that many food products are based on cereals (such as bread, pasta, cookies, baby food, and confectionery), the surveillance of these toxic substances is imperative. Although acute mycotoxicosis by EAs is rare, EAs remain a source of concern for human and animal health as food contamination by EAs has recently increased. Environmental conditions, such as low temperatures and humid weather before and during flowering, influence contamination agricultural products by EAs, contributing to the Citation: Agriopoulou, S. Ergot Alkaloids Mycotoxins in Cereals and appearance of outbreak after the consumption of contaminated products. The present work aims to Cereal-Derived Food Products: present the recent advances in the occurrence of EAs in some food products with emphasis mainly Characteristics, Toxicity, Prevalence, on grains and grain-based products, as well as their toxicity and control strategies.
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And

    Upregulation of Peroxisome Proliferator-Activated Receptor-Α And

    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
  • New Markers in the Mycotox Profile

    New Markers in the Mycotox Profile

    New Markers in the MycoTOX Profile We are happy to announce the addition of four new mycotoxin markers to our MycoTOX Profile. The test now includes 11 mycotoxins from 40 species of mold, making it by far the most comprehensive and competitively priced mycotoxin test available. It also still more sensitive and accurate than other tests available, because we use LC/MS/MS technology. Here is an overview of the four new mycotoxin markers: Gliotoxin Gliotoxin (GTX) is produced by the mold genus Aspergillus. Aspergillus spreads in the environment by releasing conidia which are capable of infiltrating the small alveolar airways of individuals. In order to evade the body’s defenses Aspergillus releases Gliotoxin to inhibit the immune system. One of the targets of Gliotoxin is PtdIns (3,4,5) P3. This results in the downregulation of phagocytic immune defense, which can lead to the exacerbation of polymicrobial infections. Gliotoxin impairs the activation of T-cells and induces apoptosis in monocytes and in monocyte-derived dendritic cells. These impairments can lead to multiple neurological syndromes. Mycophenolic Acid Mycophenolic Acid (MPA) produced by the Penicillium fungus. MPA is an immunosuppressant which inhibits the proliferation of B and T lymphocytes. MPA exposure can increase the risk of opportunistic infections such as Clostridia and Candida. MPA is associated with miscarriage and congenital malformations when the woman is exposed in pregnancy. Dihydrocitrinone Dihydrocitrinone is a metabolite of Citrinin (CTN), which is a mycotoxin that is produced by the mold species Aspergillus, Penicillium, and Monascus. CTN exposure can lead to nephropathy, because of its ability to increase permeability of mitochondrial membranes in the kidneys.
  • Cabergoline Monograph

    Cabergoline Monograph

    Cabergoline DRUG NAME: Cabergoline SYNONYM(S): COMMON TRADE NAME(S): DOSTINEX® CLASSIFICATION: hormonal agent Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM OF ACTION: Cabergoline is a dopaminergic ergot derivative with longer lasting prolactin lowering activity than bromocriptine. Cabergoline may decrease hormone production and the size of prolactin-dependent pituitary adenomas1 by inhibiting the release and synthesis of prolactin from the anterior pituitary gland.2,3 The prolactin lowering effect is dose-related.2 PHARMACOKINETICS: Oral Absorption rapidly absorbed, unaffected by food Distribution widely distributed,4 time to peak 2-3 h, steady state achieved after 4 weeks cross blood brain barrier? yes volume of distribution no information found plasma protein binding 40-42% Metabolism extensive hepatic metabolism, primarily via hydrolysis with minimal CYP450 mediated metabolism; undergoes first-pass metabolism active metabolite(s) no information found inactive metabolite(s)4-6 eight metabolites including 6-allyl-8b-carboxy-ergoline Excretion primarily hepatic7 urine7 18-22%, <4% unchanged after 20 days feces7 60-72% after 20 days terminal half life 63-69 h, hyperprolactinemic patients: 79-115 h clearance no information found Sex no significant differences found7 Elderly no significant differences found7 Adapted from standard reference2 unless specified otherwise. USES: Primary uses: Other uses: *Pituitary tumours *Health Canada approved indication SPECIAL PRECAUTIONS: Contraindications2:
  • Immunopathology of Aspergillus Infections in Children with Chronic Granulomatous Disease and Cystic Fibrosis

    Immunopathology of Aspergillus Infections in Children with Chronic Granulomatous Disease and Cystic Fibrosis

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Aberdeen University Research Archive Immunopathology of Aspergillus Infections in Children with Chronic Granulomatous Disease and Cystic Fibrosis. Adilia Warris, MD PhD MRC Centre for Medical Mycology, Aberdeen Fungal Group, Institute of Medical Sciences, University of Aberdeen, UK. Corresponding address: Medical Research Council Centre for Medical Mycology at the University of Aberdeen, Aberdeen Fungal Group, Institute of Medical Sciences, Foresterhill, AB25 2ZD, Aberdeen, UK. Phone: +44 (0)1224437596. Fax: +44 (0)1224437506. E-mail: [email protected] Acknowledgements AW is supported by the Wellcome Trust Strategic Award (grant 097377) and the MRC Centre for Medical Mycology (grant MR/N006364/1) at the University of Aberdeen. Key Words: chronic granulomatous disease, cystic fibrosis, Aspergillus, aspergillosis, inflammation Abbreviated title: Aspergillus infections in CGD and CF Running head title: Aspergillus infections in CGD and CF Introduction Children with chronic granulomatous disease (CGD) and cystic fibrosis (CF) share some important clinical characteristics which are the consequence of their intrinsic susceptibility to recurrent and opportunistic infections and exaggerated inflammation. Although the clinical phenotypes of Aspergillus disease differ substantially between those two non-neutropenic patient groups, the underlying pathophysiology show remarkable commonalities with excessive inflammation being a hallmark of Aspergillus disease. The occurrence of Aspergillus infections in these two patient populations is associated with decreased quality of life and premature death. Our knowledge of the pathophysiology of Aspergillus infections is mainly derived from infections caused by a single species - Aspergillus fumigatus - in the neutropenic host. The insights obtained in this setting do not translate well to the non-neutropenic host.
  • Fungal Keratitis: Immune Recognition, Neutrophil-Hyphae Interactions, And

    Fungal Keratitis: Immune Recognition, Neutrophil-Hyphae Interactions, And

    FUNGAL KERATITIS: IMMUNE RECOGNITION, NEUTROPHIL-HYPHAE INTERACTIONS, AND FUNGAL ANTI-OXIDATIVE DEFENSES by SIXTO MANUEL LEAL JR. Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Thesis Advisor: Eric Pearlman, Ph.D. Department of Pathology CASE WESTERN RESERVE UNIVERSITY August, 2012 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the dissertation of ______________________________________________________ candidate for the Ph.D. degree *. (signed)_______________________________________________ (chair of the committee) ________________________________________________ ________________________________________________ ________________________________________________ ________________________________________________ ________________________________________________ (date) _______________________ *We also certify that written approval has been obtained for any proprietary material contained therein. Dedication I dedicate this cumulative work to the invisible hand that has blessed my personal and academic life with incredible people, guidance, talent, courage, perseverance, and productivity. 3 Table of Contents List of Figures 7 List of Tables 9 Acknowledgements 10 List of Abbreviations 12 Abstract 14 Chapter 1. Introduction Fungi in their natural environment 16 Fungi and human disease 18 Fungi that cause human corneal infection 21 Fungal keratitis- Clinical characteristics and outcome 22 Anti-microbial Defenses at the Ocular Surface 23 Immune Recognition of Fungi 27 β2 integrins
  • Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation

    Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation

    www.sciencemag.org/cgi/content/full/327/5963/348/DC1 Supporting Online Material for Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation Jason Rihel,* David A. Prober, Anthony Arvanites, Kelvin Lam, Steven Zimmerman, Sumin Jang, Stephen J. Haggarty, David Kokel, Lee L. Rubin, Randall T. Peterson, Alexander F. Schier* *To whom correspondence should be addressed. E-mail: [email protected] (A.F.S.); [email protected] (J.R.) Published 15 January 2010, Science 327, 348 (2010) DOI: 10.1126/science.1183090 This PDF file includes: Materials and Methods SOM Text Figs. S1 to S18 Table S1 References Supporting Online Material Table of Contents Materials and Methods, pages 2-4 Supplemental Text 1-7, pages 5-10 Text 1. Psychotropic Drug Discovery, page 5 Text 2. Dose, pages 5-6 Text 3. Therapeutic Classes of Drugs Induce Correlated Behaviors, page 6 Text 4. Polypharmacology, pages 6-7 Text 5. Pharmacological Conservation, pages 7-9 Text 6. Non-overlapping Regulation of Rest/Wake States, page 9 Text 7. High Throughput Behavioral Screening in Practice, page 10 Supplemental Figure Legends, pages 11-14 Figure S1. Expanded hierarchical clustering analysis, pages 15-18 Figure S2. Hierarchical and k-means clustering yield similar cluster architectures, page 19 Figure S3. Expanded k-means clustergram, pages 20-23 Figure S4. Behavioral fingerprints are stable across a range of doses, page 24 Figure S5. Compounds that share biological targets have highly correlated behavioral fingerprints, page 25 Figure S6. Examples of compounds that share biological targets and/or structural similarity that give similar behavioral profiles, page 26 Figure S7.
  • PESTICIDE EVALUATION REPORT and SAFER USE ACTION PLAN(PERSUAP)

    PESTICIDE EVALUATION REPORT and SAFER USE ACTION PLAN(PERSUAP)

    PESTICIDE EVALUATION REPORT and SAFER USE ACTION PLAN(PERSUAP) By the USAID Kenya Agricultural Value Chain Enterprises (USAID-KAVES) Project Revised March 2014 This publication was produced for review by the United States Agency for International Development. It was prepared by Fintrac Inc. under contract reference AID-623-C-13-00002 Fintrac Inc. www.fintrac.com [email protected] US Virgin Islands 3077 Kronprindsens Gade 72 St. Thomas, USVI 00802 Tel: (340) 776-7600 Fax: (340) 776-7601 Washington, D.C. 1400 16th Street NW, Suite 400 Washington, D.C. 20036 USA Tel: (202) 462-3304 Fax: (202) 462-8478 USAID-KAVES Karen Office Park 3rd Floor Baobab, Suite H Langata Road, Karen, Nairobi Prepared by Fintrac Inc. USAID-KAVES PERSUAP 3 KENYA AGRICULTURAL VALUE CHAIN ENTERPRISES PROJECT (KAVES) PESTICIDE EVALUATION REPORT and SAFER USE ACTION PLAN (PERSUAP) Revised March 20134 The author’s views expressed in this publication do not necessarily reflect the views of the United States Agency for International Development or the United States government. Photos by Fintrac Inc. and Real IPM. Prepared by Fintrac Inc. INITIAL ENVIRONMENTAL EXAMINATION, AMENDMENTPESTICIDE EVALUATION REPORT AND SAFER USE ACTION PLAN (PERSUAP) FOR USAID/KENYA’S KENYA AGRICULTURAL VALUE CHAIN ENTERPRISES (KAVES) PROJECT CONTRACT NO. AID-623-C-13-00002 PROJECT NAME: Kenya Agricultural Value Chain Enterprises (KAVES) Project REGION/COUNTRY: East Africa/Kenya PROGRAM AREA: 4.5 Agriculture, Feed the Future ORIGINATING OFFICE Agriculture Business and Environment Office CURRENT DATE (as of revisions): March 2014 IEE AMENDMENT: Yes PREPARED BY: Fintrac Inc. IMPLEMENTATION START: January 16, 2013 LOP AMOUNT: $39,810,558 IMPLEMENTATION END: January 15th 2018 Filename & date of original IEE: Kenya_FY09_EconGrowth_IEE_01xx09.doc The purpose of this IEE amendment is to approve the 2013 Pesticide Evaluation Report (PER) and Safer Use Action Plan (SUAP) developed under the KAVES project and which will be used during project implementation.
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
  • 4 Supplementary File

    4 Supplementary File

    Supplemental Material for High-throughput screening discovers anti-fibrotic properties of Haloperidol by hindering myofibroblast activation Michael Rehman1, Simone Vodret1, Luca Braga2, Corrado Guarnaccia3, Fulvio Celsi4, Giulia Rossetti5, Valentina Martinelli2, Tiziana Battini1, Carlin Long2, Kristina Vukusic1, Tea Kocijan1, Chiara Collesi2,6, Nadja Ring1, Natasa Skoko3, Mauro Giacca2,6, Giannino Del Sal7,8, Marco Confalonieri6, Marcello Raspa9, Alessandro Marcello10, Michael P. Myers11, Sergio Crovella3, Paolo Carloni5, Serena Zacchigna1,6 1Cardiovascular Biology, 2Molecular Medicine, 3Biotechnology Development, 10Molecular Virology, and 11Protein Networks Laboratories, International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 34149, Trieste, Italy 4Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy 5Computational Biomedicine Section, Institute of Advanced Simulation IAS-5 and Institute of Neuroscience and Medicine INM-9, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany 6Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy 7National Laboratory CIB, Area Science Park Padriciano, Trieste, 34149, Italy 8Department of Life Sciences, University of Trieste, Trieste, 34127, Italy 9Consiglio Nazionale delle Ricerche (IBCN), CNR-Campus International Development (EMMA- INFRAFRONTIER-IMPC), Rome, Italy This PDF file includes: Supplementary Methods Supplementary References Supplementary Figures with legends 1 – 18 Supplementary Tables with legends 1 – 5 Supplementary Movie legends 1, 2 Supplementary Methods Cell culture Primary murine fibroblasts were isolated from skin, lung, kidney and hearts of adult CD1, C57BL/6 or aSMA-RFP/COLL-EGFP mice (1) by mechanical and enzymatic tissue digestion. Briefly, tissue was chopped in small chunks that were digested using a mixture of enzymes (Miltenyi Biotec, 130- 098-305) for 1 hour at 37°C with mechanical dissociation followed by filtration through a 70 µm cell strainer and centrifugation.
  • Allergic Bronchopulmonary Aspergillosis and Severe Asthma with Fungal Sensitisation

    Allergic Bronchopulmonary Aspergillosis and Severe Asthma with Fungal Sensitisation

    Allergic Bronchopulmonary Aspergillosis and Severe Asthma with Fungal Sensitisation Dr Rohit Bazaz National Aspergillosis Centre, UK Manchester University NHS Foundation Trust/University of Manchester ~ ABPA -a41'1 Severe asthma wl'th funga I Siens itisat i on Subacute IA Chronic pulmonary aspergillosjs Simp 1Ie a:spe rgmoma As r§i · bronchitis I ram une dysfu net Ion Lun· damage Immu11e hypce ractivitv Figure 1 In t@rarctfo n of Aspergillus Vliith host. ABP A, aHerg tc broncho pu~ mo na my as µe rgi ~fos lis; IA, i nvas we as ?@rgiH os 5. MANCHl·.'>I ER J:-\2 I Kosmidis, Denning . Thorax 2015;70:270–277. doi:10.1136/thoraxjnl-2014-206291 Allergic Fungal Airway Disease Phenotypes I[ Asthma AAFS SAFS ABPA-S AAFS-asthma associated with fu ngaIsensitization SAFS-severe asthma with funga l sensitization ABPA-S-seropositive a llergic bronchopulmonary aspergi ll osis AB PA-CB-all ergic bronchopulmonary aspergi ll osis with central bronchiectasis Agarwal R, CurrAlfergy Asthma Rep 2011;11:403 Woolnough K et a l, Curr Opin Pulm Med 2015;21:39 9 Stanford Lucile Packard ~ Children's. Health Children's. Hospital CJ Scanford l MEDICINE Stanford MANCHl·.'>I ER J:-\2 I Aspergi 11 us Sensitisation • Skin testing/specific lgE • Surface hydroph,obins - RodA • 30% of patients with asthma • 13% p.atients with COPD • 65% patients with CF MANCHl·.'>I ER J:-\2 I Alternar1a• ABPA •· .ABPA is an exagg·erated response ofthe imm1une system1 to AspergUlus • Com1pUcatio n of asthm1a and cystic f ibrosis (rarell·y TH2 driven COPD o r no identif ied p1 rior resp1 iratory d isease) • ABPA as a comp1 Ucation of asth ma affects around 2.5% of adullts.